Self Study 2024 Release II: Neoadjuvant Immunotherapy Updates in NSCLC, Colon, and Rectal Cancer
Recent advancements have expanded the use of immune checkpoint inhibitors (ICI) in the neoadjuvant setting to early stage non-small-cell lung cancer (NSCLC), colon and rectal cancer. The purpose of this module is to review updates for use of ICI in the neoadjuvant setting. This will include a review of safety and efficacy data of pembrolizumab in NSCLC, review of predictive biomarkers in rectal and colon cancer, and safety and efficacy data of dostarlimab in rectal cancer.
Course Information
Neoadjuvant Immunotherapy Updates in NSCLC, Colon, and Rectal Cancer
UAN# 0465-0000-24-105-H01-P
Author: Sarah Shockley, PharmD, BCOP
Learning Objectives
- Apply recent advances in the use of pembrolizumab in the neoadjuvant setting to early-stage NSCLC patients.
- Review the safety and efficacy data of dostarlimab in the neoadjuvant setting in locally advanced rectal cancer.
- Interpret current evidence with predictive biomarkers for regimen selection in the neoadjuvant setting for rectal and colon cancer.
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.